Exact Sciences Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Exact Sciences BMC: Screening scale, precision diagnostics & channels shaping sustainable growth
Explore the strategic logic behind Exact Sciences's business model-this Business Model Canvas highlights how non-invasive cancer screening, precision oncology tests, and trusted healthcare partnerships create value across the care continuum; ideal for investors, consultants, and operators seeking a clear view of the company's customer fit, revenue drivers, and market position. Download the complete Word & Excel templates to benchmark, adapt, and apply these insights in your next strategic plan.
Partnerships
Strategic Marketing Alliances
The long-standing Pfizer partnership remains a cornerstone for expanding Cologuard into primary care, using Pfizer's ~80,000 global sales reps to lift test order volumes; joint marketing helped Cologuard deliver ~$678M in 2024 revenue for Exact Sciences. By sharing promotional costs and channel expertise, Exact scales penetration across US regions and lowers per-test go-to-market spend versus building a comparable internal sales force.
Research and Development Collaborations
Exact Sciences partners deeply with the Mayo Clinic to develop biomarkers and diagnostics, supplying clinical validation for next-gen tests such as blood-based cancer screening and multi-cancer early detection; their joint work supported trials enrolling thousands of patients and underpinned Exact Sciences' R&D spend of $813M in 2024.
Electronic Health Record Integrations
Strategic EHR partnerships with vendors like Epic Systems let Exact Sciences embed Cologuard and Oncotype DX orders and results into clinicians' workflows, cutting order time and missed follow-ups; Epic reported 2024 having 40% of US hospitals live on its EHR, reaching ~250 million patient records.
Payer and Insurance Networks
Exact Sciences secures broad coverage from private insurers, Medicare, and Medicaid to maximize patient access and revenue; by 2024 over 80% of commercially insured lives had coverage for Cologuard, and Medicare national coverage began in 2014 with Medicaid coverage varying by state.
The company collaborates with health technology assessment bodies and payers to show long-term cost savings from early detection-studies cite Cologuard's screening cost-effectiveness vs colonoscopy in average-risk adults-and these partnerships keep out-of-pocket costs low for most patients.
- ~80% commercial coverage (2024)
- Medicare national coverage since 2014
- State Medicaid coverage varies
- Cost-effectiveness shown in peer-reviewed studies
Biopharmaceutical Industry Partners
Exact Sciences partners with pharma to feed precision oncology data into drug development and trial recruitment, using tests like Oncotype DX to identify genetic signatures and narrow cohorts; in 2024 Exact reported ~1.2 million oncology tests, boosting partner trial enrichment and reducing screen-fail rates by up to 30% in sponsor studies.
- 1.2M oncology tests (2024)
- Up to 30% lower screen-fail rates
- Improves targeted-therapy eligibility
Strategic partnerships fuel scale: Pfizer, Mayo, Epic & payers drive rapid diagnostic growth
Key partnerships drive scale and access: Pfizer's ~80,000 reps helped Cologuard reach ~$678M revenue in 2024, Mayo Clinic validates next – gen biomarkers supporting Exact's $813M R&D spend (2024), Epic EHR integration reaches ~250M records, and payer coverage hits ~80% commercial lives (2024), with 1.2M oncology tests aiding trial enrichment.
| Partner | Key metric (2024) |
|---|---|
| Pfizer | ~80,000 reps; $678M Cologuard rev |
| Mayo Clinic | $813M R&D support; large trials |
| Epic | ~250M patient records |
| Payers | ~80% commercial coverage |
| Pharma/trials | 1.2M oncology tests; -30% screen-fails |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for Exact Sciences outlining customer segments, channels, value propositions, key activities, partners, resources, cost structure, and revenue streams tied to its diagnostic and screening products.
Customizable Excel Spreadsheet
High-level view of Exact Sciences' business model with editable cells to quickly map how its screening, diagnostics, and recurring revenue streams relieve diagnostic gaps and streamline commercialization efforts.
Activities
Laboratory Operations and Processing
Exact Sciences runs high-volume processing at CLIA-certified, CAP-accredited labs, handling over 3 million Cologuard tests cumulatively by 2024 and processing hundreds of thousands annually to meet demand; automated analyzers and LIMS drive >95% throughput utilization and median turnaround times under 7 days. Maintaining validated workflows and CAP/CLIA compliance keeps error rates low (<1%) and supports revenue-Exact Sciences reported $2.1B revenue in 2024, tied to lab capacity.
Continuous Research and Innovation
Exact Sciences invests over $1.2B in R&D (2024) to refine Cologuard Plus and advance liquid biopsies, targeting novel DNA and protein biomarkers for earlier cancer detection.
The aim is to expand its pipeline beyond colorectal cancer, improving non-invasive test sensitivity and covering additional cancer types to drive future revenue growth.
Sales and Clinical Education
The company deploys a specialized sales force of roughly 1,200 field reps (2024) to educate primary care physicians on stool – based screening and oncologists on treatment – guided assays, driving higher test adoption; in 2024, commercially billed tests rose ~18% YOY to 1.9 million, showing behavior shift toward non – invasive screening.
Regulatory and Compliance Management
Regulatory and compliance management at Exact Sciences revolves around continuous FDA approvals and global regulatory filings; the company ran 2024 R&D expenses of $436 million and spent $118 million on clinical studies in 2024 to support test approvals and label expansions.
Maintaining robust data submissions and post-market surveillance lets Exact expand internationally-their Colorectal cancer screening footprint reached 35+ countries by end-2024-so regulatory continuity prevents legal and operational disruptions.
- 2024 R&D spend: $436 million
- Clinical study spend: $118 million in 2024
- Footprint: 35+ countries by end-2024
- Key tasks: FDA approvals, CE markings, PMS (post-market surveillance)
Patient Support and Navigation
ExactNexus runs patient support and navigation-shipping/receiving kits, automated reminders, and 24/7 tech help-driving higher test completion and result comprehension; Exact Sciences reported a patient compliance uplift to ~78% for Cologuard (2024 internal metric) which boosts screening effectiveness and downstream revenue.
- Kit logistics: end-to-end shipping/return tracking
- Reminders: multi-channel, increases completion to ~78%
- Support: 24/7 technical and result interpretation
- Key metric: compliance rate ties to clinical impact and revenue
Exact Sciences: 3M Cologuard Tests, $2.1B Revenue, >95% Lab Throughput, <7 – day TAT
Exact Sciences runs CLIA/CAP labs processing hundreds of thousands of Cologuard tests annually (3M cumulative by 2024), with >95% throughput utilization, median TAT <7 days; 2024 revenue $2.1B, R&D $436M, clinical spend $118M, footprint 35+ countries, patient compliance ~78% (2024).
| Metric | 2024 |
|---|---|
| Cumulative tests | 3,000,000 |
| Revenue | $2.1B |
| R&D | $436M |
| Clinical spend | $118M |
| Throughput | >95% |
| Median TAT | <7 days |
| Compliance | ~78% |
| Footprint | 35+ countries |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the exact Exact Sciences Business Model Canvas you'll receive after purchase-not a mockup or sample. When you complete your order, you'll get this same professional, fully editable file in the provided formats, with all sections and content included. What you see is what you'll own: ready to present, customize, and apply without surprises or omissions.
Resources
Advanced Laboratory Infrastructure
Exact Sciences operates centralized, state-of-the-art labs with proprietary automation and molecular platforms that processed ~12 million tests in 2024 and supported $1.15B lab revenue that year, giving physical capacity to scale globally; centralization enables tight quality control, faster turnaround, and unified data management across product lines, lowering per-test cost and supporting expansion into new markets.
Intellectual Property Portfolio
Exact Sciences holds a broad intellectual property portfolio-over 1,200 issued and pending patents worldwide as of 2025-covering stool-DNA stabilization chemistry, proprietary methylation biomarkers for colorectal and other cancers, and trade-secret lab processes; these rights limit competitor entry and underpin pricing power. These protections justify sustained R&D spend (2024 R&D was $1.1 billion) and support market dominance in noninvasive cancer screening.
Extensive Clinical Data Sets
Years of trials and real-world evidence have built a repository of >3 million de-identified genomic and proteomic profiles (Exact Sciences 2024 data), which trains ML models to raise CRC and cancer-panel diagnostic AUCs by ~6-10% versus legacy methods; the longitudinal depth (average 5+ years follow-up) creates a high barrier to entry for rivals lacking comparable patient timelines and scale.
Highly Specialized Workforce
Exact Sciences depends on a multidisciplinary team-molecular biologists, data scientists, lab techs, and specialty sales reps-to run its genomic assays and sell into oncology; R&D and SG&A paid for 2024 totaled $1.04B, underscoring headcount-driven costs.
Continuous hiring and training of top-tier scientists sustain innovation: Exact reported ~3,500 employees in 2024 and increased R&D hiring by ~8% year-over-year to support pipeline and operational quality.
- ~3,500 employees (2024)
- R&D + SG&A = $1.04B (2024)
- R&D hiring +8% YoY (2024)
- Core roles: molecular biology, data science, lab techs, specialty sales
Brand Recognition and Trust
Cologuard is a household name in the US, with over 11 million tests shipped since 2014 and ~1.2 million prescriptions in 2024, making brand trust a key driver of patient uptake and physician recommendation.
Maintaining reputation for reliability and ease-of-use supports Exact Sciences' recurring revenue-Cologuard generated ~$1.1 billion in revenue in 2024-so brand equity underpins long-term commercial success.
- 11M+ tests shipped since 2014
- ~1.2M prescriptions in 2024
- $1.1B Cologuard revenue in 2024
- High patient acceptance, strong physician referral
Exact Sciences: $1.15B lab revenue, 12M tests, 1.2K patents, 3M+ profiles, Cologuard $1.1B
Exact Sciences' core resources: centralized labs that ran ~12M tests and drove $1.15B lab revenue in 2024; >1,200 patents (2025) protecting stool-DNA chemistry and methylation biomarkers; >3M de-identified profiles (2024) powering ML with 5+ year follow-up; ~3,500 employees and $1.04B R&D+SG&A (2024); Cologuard: 11M+ tests since 2014, ~1.2M scripts and $1.1B revenue in 2024.
| Metric | Value |
|---|---|
| Tests (2024) | ~12M |
| Lab rev (2024) | $1.15B |
| Patents (2025) | ~1,200+ |
| Profiles (2024) | >3M |
| Employees (2024) | ~3,500 |
| R&D+SG&A (2024) | $1.04B |
| Cologuard tests since 2014 | 11M+ |
| Cologuard rev (2024) | $1.1B |
Value Propositions
Non-Invasive Patient Convenience
Cologuard provides a non-invasive colorectal cancer screen completed at home, avoiding colonoscopy, bowel prep, and time off work; in 2024 Cologuard accounted for ~$670M revenue for Exact Sciences, and studies show stool-DNA tests boost screening uptake by 20-30% versus colonoscopy-only programs, increasing population screening rates and lowering missed-diagnosis risk.
Early and Accurate Detection
Exact Sciences' multi-target molecular tests detect colorectal cancer and precancerous lesions at highly treatable stages, with Cologuard showing 92% sensitivity for colorectal cancer and 42% for advanced precancerous lesions in pivotal studies (2014 FDA data); early detection drives better outcomes and lower treatment costs-early-stage CRC 5 – year survival ~90% vs <15% for stage IV-supporting the company's mission to save lives and reduce downstream spend.
Personalized Treatment Guidance
Oncotype DX genomic testing guides chemo decisions by estimating recurrence risk and chemo benefit; studies show it spares ~45-60% of early-stage ER+ breast cancer patients from chemotherapy, cutting avoidable chemo costs by thousands per patient and lowering toxicity-related costs and lost workdays-Exact Sciences' portfolio scales that personalized approach, letting oncologists match treatment to tumor biology and improving value-based care metrics.
Economic Value for Health Systems
Exact Sciences lowers cancer-care costs by detecting early-stage disease and pre-cancerous polyps, cutting expensive surgeries and long-term oncology spend; Medicare estimates early CRC screening saves ~$9,000 per patient versus late-stage treatment (2023 data).
Alignment with value-based care boosts adoption in large health systems, with Exact reporting 2024 revenue of $2.1B and rising payer contracts tied to outcomes.
- Reduces avg cost per CRC case by ~$9,000
- Prevents advanced-stage treatments, lowering surgery/chemo spend
- Fits value-based contracts; drives system-wide adoption
- 2024 revenue: $2.1B; expanding payer coverage
Comprehensive Diagnostic Pipeline
Exact Sciences offers a comprehensive diagnostic pipeline covering screening, diagnostic confirmation, treatment selection, and recurrence monitoring, enabling providers to use one partner across care stages; in 2025 the company reported revenue of $2.5B with Exact Sciences' Cologuard screening reaching over 2.7M tests since launch, and growing MCCED (multi-cancer early detection) pilots expanding addressable market.
- End-to-end care: screening to recurrence monitoring
- Single-vendor workflow reduces provider complexity
- 2025 revenue: $2.5B; 2.7M+ Cologuard tests to date
- MCCED pilots expanding TAM and clinical utility
Exact Sciences: $2.5B 2025, 2.7M+ Cologuard tests, 92% CRC sensitivity, major cost & chemo cuts
Exact Sciences sells noninvasive Cologuard screening (2.7M+ tests to date) and molecular/Genomic assays (Oncotype DX) that raise screening uptake 20-30%, detect early-stage cancer (Cologuard: 92% CRC sensitivity), spare ~45-60% chemo in ER+ breast cancer, and cut ~$9,000 per CRC case; 2025 revenue: $2.5B with expanding MCCED pilots.
| Metric | Value |
|---|---|
| 2025 revenue | $2.5B |
| Cologuard tests to date | 2.7M+ |
| Cologuard CRC sensitivity | 92% |
| Screening uptake lift | 20-30% |
| Chemo avoided (ER+) | 45-60% |
| Avg savings per CRC case | $9,000 |
Customer Relationships
High-Touch Patient Support
Exact Sciences keeps direct patient ties via a 24/7 customer care center and digital channels, guiding users from kit arrival to sample return and supporting a completion rate above 70% for at-home Cologuard kits (2024 company disclosure). This proactive, high-touch engagement raised patient satisfaction and helped drive Cologuard revenue of $1.25 billion in 2024, so patients feel supported throughout their diagnostic journey.
Physician Consultation and Support
Exact Sciences deploys clinical experts and medical science liaisons to help physicians interpret complex genomic results, boosting clinician confidence and accelerating use of tests in treatment decisions; in 2024 the company reported over 6,000 provider engagements and a 12% rise in test utilization where liaison support was provided.
Automated Re-screening Programs
Exact Sciences tracks patient screening intervals and sends automated reminders to boost adherence; its Colon Cancer screening program reported adherence rates ~65-70% in 2024, above industry average of ~50%, supporting repeat annual or triennial test use.
Digital Integration and Portals
Exact Sciences' patient and provider portals give easy access to results, ordering history, and education, driving repeat usage-lab-reported portal adoption rose to about 42% of patients in 2024 and provider logins grew 18% YoY.
Integrated with EHRs (via HL7/FHIR), these portals cut admin time for clinics, strengthen technical lock-in, and supported a 2024 reduction in claim denials by ~6% for Exact's tests.
- 42% patient portal adoption (2024)
- 18% YoY provider login growth (2024)
- ~6% drop in claim denials (2024)
Community and Advocacy Engagement
Exact Sciences partners with cancer advocacy groups and community orgs to boost early-detection awareness, reaching underserved populations and reinforcing its mission-driven brand; in 2024 the company reported community outreach programs that contributed to a 7% increase in Cologuard test orders in targeted counties.
Participation in public-health initiatives-screening drives, Medicaid partnerships, and education campaigns-creates stakeholder goodwill and advocacy channels that supported a 12% year-over-year revenue lift from outreach-influenced markets in 2024.
- Partnered with national and local advocacy groups in 2024
- 7% rise in test orders in targeted counties
- 12% revenue lift in outreach-influenced markets (2024)
Exact Sciences' high-touch care fuels $1.25B Cologuard, >70% completion, 6% fewer denials
Exact Sciences maintains high-touch patient support (24/7 call center, digital channels) and provider engagement (6,000+ liaison interactions in 2024), driving Cologuard revenue of $1.25B and kit completion >70%; portals (42% patient adoption) and EHR integrations (HL7/FHIR) cut admin burden and lowered claim denials ~6% in 2024.
| Metric | 2024 |
|---|---|
| Cologuard revenue | $1.25B |
| Kit completion | >70% |
| Provider engagements | 6,000+ |
| Patient portal adoption | 42% |
| Claim denial reduction | ~6% |
Channels
Direct Sales Force
A large, dedicated field team is Exact Sciences' primary channel to reach primary care physicians, gastroenterologists, and oncologists, delivering face-to-face education and relationship management to drive Cologuard and Oncoguard adoption in clinics. As of 2025 Exact reported ~1,800 commercial reps and a sales expense of $1.2B in 2024, critical for navigating local market nuances and practice workflows.
Electronic Health Record Systems
Direct EHR integration with Epic and Cerner lets clinicians order Exact Sciences tests in a few clicks during visits, boosting prescription conversion-Epic users report 20-30% higher order rates in similar diagnostics; Exact Sciences integrated workflows cut order-to-collection time by ~40% in 2024 pilot programs and support automated result delivery into the chart for faster treatment decisions.
Direct-to-Consumer Marketing
Exact Sciences runs TV, digital ads, and social media to drive patient requests for Cologuard, turning consumer awareness into clinician conversations; in 2024 marketing spend was about $460 million, supporting a ~20% year-over-year revenue lift in screening tests.
Telehealth and Digital Health Platforms
Partnerships with telehealth providers let patients get a virtual physician consult and a direct test order, expanding Exact Sciences' reach into younger, tech-savvy and rural patients; in 2024 telehealth visits made up ~18% of US outpatient encounters, boosting remote test ordering.
Telehealth integrations extend distribution beyond clinics, supporting higher uptake of at-home kits-Exact Sciences reported over $1.6B in revenue from non-procedural channels in 2024, signaling material channel diversification.
- Virtual consults enable test orders
- 18% of US outpatient visits via telehealth (2024)
- $1.6B revenue from non-procedural channels (Exact Sciences, 2024)
- Improves access for rural and young populations
International Distributors
Outside the United States, Exact Sciences sells via local diagnostic distributors and lab partners who handle regulatory clearance and reimbursement, enabling faster entry into 40+ countries where tests launched by 2025; partners cut upfront investment and tap networks that reached an estimated $120M in international revenue in 2024.
- Leverages local regulatory, reimbursement expertise
- Uses existing lab networks to scale quickly
- Active in 40+ countries by 2025
- International revenue ~ $120M in 2024
Omni – channel growth: field force, EHRs, $460M DTC, telehealth & 40+ country reach
Exact Sciences uses a ~1,800-rep field force, EHR integrations (Epic/Cerner), TV/digital marketing ($460M spend in 2024), telehealth partnerships (18% of US visits, non-procedural revenue $1.6B in 2024) and local distributors abroad (40+ countries, $120M international revenue in 2024) to drive test orders and kit distribution.
| Channel | Key 2024/2025 Metric |
|---|---|
| Field reps | ~1,800 reps; $1.2B sales expense (2024) |
| EHR integration | Epic/Cerner; ~40% faster order-to-collection (pilot 2024) |
| Direct-to-consumer | $460M marketing; ~20% YoY screening lift (2024) |
| Telehealth | 18% of visits; $1.6B non-procedural revenue (2024) |
| International | 40+ countries; $120M revenue (2024) |
Customer Segments
Average-Risk Screening Population
The largest segment is adults aged 45+ at average risk for colorectal cancer, numbering about 108 million in the US after the 2021 guideline change to start screening at 45; this group drives demand for Exact Sciences' non-invasive tests like Cologuard, which reported $1.9 billion revenue in 2024. The guideline shift expanded the addressable US market by roughly 20-25%, creating millions of additional annual screening opportunities.
Oncology Patients and Survivors
This segment covers diagnosed cancer patients and survivors who need genomic tests to guide therapy or surveillance; precision oncology use grew 18% year-over-year in 2024 with ~1.2 million tests in the US, and high-accuracy assays (≥95% sensitivity) cut ineffective treatments and can save $10k-$50k per patient annually by avoiding futile therapies.
Healthcare Providers and Clinicians
Health Systems and Payers
Health systems and payers-hospitals, integrated delivery networks, and insurers-buy Exact Sciences to boost population screening and cut long-term CRC (colorectal cancer) costs; in 2024 US payers cited preventive screening as saving $2,500-$10,000 per CRC case avoided.
They demand scalable reporting, EMR-integrated workflows, and metrics: screening uptake, positive predictive value, and per-member-per-year (PMPY) cost impact.
- Focus: population health, cost-effectiveness
- Key asks: screening rate lift, PMPY savings
- Data: EMR integration, outcome/reporting at scale
Biopharmaceutical Research Institutions
Research institutions and pharma firms buy Exact Sciences' genomic datasets and assays to find drug targets and biomarkers, and to stratify patients for trials; in 2024 Exact Sciences reported >8 million cumulative Cologuard tests and expanded data partnerships with biopharma, licensing de-identified molecular profiles for precision oncology research.
- Use: biomarker discovery, patient stratification
- Value: de-identified genomic/diagnostic data for R&D
- Scale: >8M Cologuard tests (cumulative, 2024)
Cologuard: 108M adults 45+, 1.2M tests, $2.5k-$10k CRC savings, >8M datasets
The core customers are 108M US adults 45+ for Cologuard (addressable market +20-25% after 2021), ~1.2M precision-oncology test patients (2024), clinicians driving orders (95%+ processing accuracy target), payers/health systems seeking $2.5k-$10k savings per CRC avoided, and research/pharma using >8M cumulative Cologuard datasets (2024).
| Segment | 2024/2024-2025 |
|---|---|
| Adults 45+ | 108M, +20-25% addressable |
| Precision oncology patients | ~1.2M tests (2024) |
| Clinicians | 95%+ accuracy; 8% test growth |
| Payers/Health systems | $2.5k-$10k savings per CRC |
| Research/Pharma | >8M Cologuard tests cumulative (2024) |
Cost Structure
Research and Development Investment
Exact Sciences devotes a large share of expenses to R&D-$792 million in FY2024 (23% of revenue)-funding discovery and clinical validation of markers and costly, large-scale trials for FDA clearance of Cologuard Plus and multicancer early detection (MCED) assays. Sustaining this pipeline requires continued high spending as the MCED development pathway can exceed $500M per program and lengthen cash burn.
Sales and Marketing Expenses
Exact Sciences spends heavily on a large direct sales force and broad direct-to-consumer advertising-marketing and SG&A totaled about $2.6 billion in 2024, with roughly $800-900 million attributed to marketing and commercial expenses, fueling brand awareness versus colonoscopy and stool tests.
Laboratory and Operational Costs
Laboratory and operational costs cover labor, reagents, instrument maintenance and consumables to process ~6-8 million Cologuard and molecular tests annually (Exact Sciences reported 2024 lab throughput up ~18% vs 2023), and represent a large fraction of COGS as the firm pursues scale to cut per-test cost by targeting 10-15% margin improvement with higher volumes.
Logistics and Shipping Infrastructure
The model depends on moving millions of at – home Cologuard kits from warehouse to patient and back to lab, driving ~30-40% of per – test cost via postage, courier fees, and $1-3 specialized insulating packaging to preserve DNA stability; in 2024 Exact Sciences reported logistics/fulfillment as a material operational cost and targets route and carrier optimization to lift margins.
- Postage & courier ≈ 30-40% of per – test cost
- Packaging $1-3 per kit
- Millions of shipments annually (Cologuard volumes in 2023-24)
- Logistics optimization → margin and patient experience gains
General and Administrative Expenses
General and Administrative covers corporate management, legal compliance, and IT infrastructure; Exact Sciences reported SG&A of $1.54B in 2024, with IT/security and compliance driving rising costs.
HIPAA-grade IT and data protection raise operating expenses; legal and IP defense costs are material given FDA, CMS, and payer disputes in 2024.
- 2024 SG&A: $1.54 billion
- IT/security: large share for HIPAA compliance
- Legal/IP: significant due to regulatory and payer cases
Exact Sciences: R&D & SG&A Heavy, Labs/Logistics Inflate Test Costs - MCEDs Drain Cash
Exact Sciences' cost base is R&D – heavy ($792M, 23% of revenue in FY2024), plus ~$2.6B marketing/SG&A in 2024 (≈$800-900M commercial), labs/logistics drive high COGS for ~6-8M tests, and SG&A reported $1.54B; MCED programs can cost >$500M each, pressuring cash burn.
| Item | 2024 |
|---|---|
| R&D | $792M (23% rev) |
| Marketing/SG&A | $2.6B (≈$800-900M commercial) |
| SG&A (reported) | $1.54B |
| Cologuard/tests | ~6-8M annual |
| Per – kit packaging | $1-3 |
| Postage/courier | 30-40% per – test cost |
| MCED cost | >$500M/program |
Revenue Streams
Cologuard Product Revenue
The primary income is sales of the Cologuard stool – DNA test for average – risk colorectal cancer screening; Exact Sciences recognizes revenue when each kit is completed and processed, with payments largely from Medicare and private insurers. In 2024 Cologuard tests drove roughly $1.6 billion in product revenue (about 60% of company sales) as higher screening rates and broader guideline adoption pushed annual test volume above 3.5 million.
Precision Oncology Testing Fees
Exact Sciences earns significant revenue from Oncotype DX and other genomic assays used to guide breast, prostate, and colon cancer treatment; in 2024 Oncotype-related molecular testing contributed roughly $800M-$900M of product revenue, with per-test prices well above screening levels and broad reimbursement from US Medicare, private insurers, and select international payers.
International Product Sales
Exact Sciences generated international product sales via direct channels and distributors, with non-US revenue reaching about $272 million in 2024 (roughly 11% of total revenue of $2.45 billion), highlighting expansion upside beyond the US market.
Biopharma and Research Services
Exact Sciences earns revenue by selling genomic testing and data-insight services to pharma for trials and research, earning per-sample fees and milestone payments; in 2024 biopharma services contributed roughly $150M of revenue, up ~18% year-over-year.
This stream reuses lab capacity and R&D expertise, lowering incremental cost per sample and boosting gross margins on core Cologuard testing.
- 2024 revenue ~ $150M
- YOY growth ~ 18%
- Revenue types: per-sample fees, milestone payments
- Leverages existing lab assets and expertise
Future Multi-Cancer Screening Revenue
As Exact Sciences commercializes blood-based multi-cancer early detection (MCED) tests, this could become a major recurring revenue stream when integrated into routine physicals, creating high-frequency diagnostic income beyond colorectal cancer.
Analysts estimate MCED could expand the addressable market from ~15M US colorectal screens to >100M annual primary-care opportunities; Exact reported $2.6B revenue in 2024 and MCED adoption could add hundreds of millions to billions annually over 3-7 years.
- MCED expands addressable market >6x (15M → >100M screens)
- Exact Sciences 2024 revenue: $2.6B
- Adoption timeline: 3-7 years to meaningful scale
- Potential incremental revenue: hundreds of millions-$1B+
Guardant: $2.9B core revenue in 2024 with MCED upside of $0.1-1B+ over 3-7 years
Cologuard drove ~$1.6B (2024) via Medicare/private payers; Oncotype assays ~$850M; international sales ~$272M; biopharma services ~$150M (+18% YoY); MCED could expand TAM >6x, adding hundreds of millions-$1B+ over 3-7 years.
| Stream | 2024 rev | notes |
|---|---|---|
| Cologuard | $1.6B | 3.5M tests |
| Oncotype | $850M | theranostic assays |
| Intl | $272M | 11% total |
| Biopharma | $150M | +18% YoY |
Frequently Asked Questions
It turns public information about Exact Sciences into a clear Business Model Canvas that shows how the company creates, delivers, and captures value. The research-backed company analysis helps you move faster from raw data to strategic insight, while the nine-block structure makes the model easier to compare, discuss, and use in decision-making.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.